Publications

Sodium-glucose co-transporter 2 inhibitors (SGLT2i) for hospitalised patients with COVID-19: prospective meta-analysis of randomised trials

LANDRAY M. et al, (2024), The Lancet Diabetes and Endocrinology

Clinical trial results in context: comparison of baseline characteristics and outcomes of 38,510 RECOVERY trial participants versus a reference population of 346,271 people hospitalised with COVID-19 in England

PESSOA-AMORIM G. et al, (2024), Trials

Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial

Mayne K. and HERRINGTON W., (2024), American Society of Nephrology. Clinical Journal

The Integration of Clinical Trials With the Practice of Medicine: Repairing a House Divided.

Angus DC. et al, (2024), JAMA

Molnupiravir or nirmatrelvir-ritonavir versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Horby PW. et al, (2024)

Effects of high-dose versus standard-dose quadrivalent influenza vaccine among patients with diabetes: A post-hoc analysis of the DANFLU-1 trial.

Lassen MCH. et al, (2024), Diabetes Obes Metab, 26, 1821 - 1829

Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis.

Cholesterol Treatment Trialists’ (CTT) Collaboration. Electronic address: ctt@ndph.ox.ac.uk None. and Cholesterol Treatment Trialists’ (CTT) Collaboration None., (2024), Lancet Diabetes Endocrinol, 12, 306 - 319

Framework of the Strengths and Challenges of Clinically Integrated Trials: An Expert Panel Report

Peters AE. et al, (2024), American Heart Journal

Effectiveness of high-dose versus standard-dose quadrivalent influenza vaccine against recurrent hospitalizations and mortality in relation to influenza circulation: A post-hoc analysis of the DANFLU-1 randomized clinical trial.

Johansen ND. et al, (2024), Clin Microbiol Infect

Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None., (2024), Lancet Child Adolesc Health

Effects of Empagliflozin on Fluid Overload, Weight and Blood Pressure in Chronic Kidney Disease

Mayne K. et al, (2023), Journal of the American Society of Nephrology

Methylprednisolone, intravenous immunoglobulin, tocilizimab or anakinra for children with Paediatric Inflammatory Multisystem Syndrome temporally associated with SARS CoV-2 (PIMS-TS, MIS-C) – report from a randomised, controlled, open-label, platform trial

LANDRAY M. et al, (2023), Lancet Child and Adolescent Health

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

PETO L. et al, (2023), Nature Communications

Effects of empagliflozin on progression of chronic kidney disease: a pre-specified secondary analysis from the EMPA-KIDNEY trial

HAYNES R. et al, (2023), Lancet Diabetes and Endocrinology

Impact of Primary Kidney Disease on the Effects of Empagliflozin in Patients with Chronic Kidney Disease: Secondary Analyses of the EMPA-KIDNEY trial

Judge P. et al, (2023), Lancet Diabetes and Endocrinology

Correction: Development and evaluation of rapid data-enabled access to routine clinical information to enhance early recruitment to the national clinical platform trial of COVID-19 community treatments.

Cake C. et al, (2023), Trials, 24

Delivering trials in the NHS: more than worth it.

Haynes R. et al, (2023), Clin Med (Lond), 23, 525 - 526

Delivering trials in the NHS: more than worth it.

Haynes R. et al, (2023), Clin Med (Lond), 23, 525 - 526

Impact of new cardiovascular events on quality of life and hospital costs in people with cardiovascular disease in the UK and US

MIHAYLOVA B. et al, (2023), Journal of the American Heart Association

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

LANDRAY M. et al, (2023), Lancet Diabetes and Endocrinology

Cookies on this website

Publications